QA OfficerOxford BioMedica (UK) Limited • Cowley, England, United Kingdom
Cette offre d'emploi n'est plus disponible
QA Officer
Oxford BioMedica (UK) Limited
- Cowley, England, United Kingdom
- Cowley, England, United Kingdom
À propos
OXB , our people are at the heart of everything we do. Were on a mission to enable life-changing therapies to reach patients around the worldand were looking for passionate individuals who embody our core values every day:
Responsible, Responsive, Resilient, and Respectful . We are currently recruiting for a
QA Officer
to join our QA Operations team. In this role, you will provide QA support for either the OXB's GMP Laboratory testing facilities or GMP Manufacturing facilities. Your responsibilities in this role would be: Overseeing quality of GMP testing operations or GMP manufacturing operations to ensure adequate and timely release of GMP compliant product. Ensuring that all documentation and quality records are reviewed and approved on batch completion and forwarded to QP for on-time batch release. Reviewing quality systems documentation including Deviations, Change Controls and CAPAs and to provide QA support to resolve compliance issues. Performing walk rounds/inspections in the GMP manufacturing areas at appropriate and quality critical stages of the testing process to ensure the testing is performed to the GMP standards. Undertaking continuous quality and process improvement for efficient way of working and to meet the current regulations. Liaising with stakeholders, e.g., laboratory/ production managers, internal customers to provide appropriate QA support and guidance to ensure compliance with GxP quality standard and any other regulations standards. Communicating updates on activities to the Management to ensure tasks are progressing and completed in timely manners. We are looking for: A level or National Certificate in a Science discipline. Higher National Certificate or Degree in science discipline desirable. A good understanding of GMP and pharmaceutical industry QA requirements. Previous experience of worked in operations within a Pharmaceuticals GMP environment. Excellent attention to detail. About us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why join us? ?? Competitive total reward packages ?? Wellbeing programmes that support your mental and physical health ?? Career development opportunities to help you grow and thrive ?? Supportive, inclusive, and collaborative culture ?? State-of-the-art labs and manufacturing facilities ?? A company that lives its values:
Responsible, Responsive, Resilient, Respect Ready to Make a Difference? Collaborate. Contribute. Change lives.
We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
TPBN1_UKTJ
Compétences linguistiques
- English
Avis aux utilisateurs
Cette offre a été publiée par l’un de nos partenaires. Vous pouvez consulter l’offre originale ici.